Ketamine and the Aging Brain: New Clues to Treatment-Resistant Depression
Ketamine has become one of the most closely watched options for people whose depression has not improved with standard antidepressants. Yet much of the evidence behind its rapid-acting effects comes from younger patients. A new analysis from Texas A&M University's Naresh K. Vashisht College of Medicine turns attention to an older population, finding that ketamine is followed by time-specific shifts in brain activity that track with clinical improvement.
The findings, published in Translational Psychiatry, could help researchers identify biological markers of ketamine's antidepressant action and explain why some patients improve while others do not. The work comes from the Experimental Psychopharmacology of Mood and Anxiety Disorders Lab, known as the EPMAD Lab.
What the Researchers Examined
The EPMAD Lab, led by Dr. Sanjay Mathew, a professor and head of psychiatry, has focused on how the brain responds to ketamine in U.S. veterans older than 55. That group is especially relevant because treatment-resistant depression can be both persistent and disabling, and because older adults often face a different risk-benefit calculation when new therapies are considered.
Dr. Nicholas Murphy, a research associate professor in the Department of Psychiatry and Behavioral Sciences at Texas A&M, coordinates the lab's neuroscience-informed treatments wing. He and colleagues analyzed resting-state brain activity after ketamine infusion, looking for patterns that unfold over time rather than a single static change.
Why Older Adults Have Been Underrepresented
Ketamine is increasingly used as a rapid-acting treatment for treatment-resistant depression. But its adoption in older adults has lagged, largely because of concerns about safety and efficacy in the context of aging pathology. Older patients may have cardiovascular issues, cognitive changes, medication interactions, or other health conditions that complicate treatment decisions.
That gap matters. If clinicians lack data specific to older adults, they may be reluctant to offer a therapy that could help, or they may use it without a clear understanding of how the aging brain responds. The Texas A&M program is designed to address that missing evidence by studying older veterans, a population with high rates of depression and substantial treatment needs.
A Floodgate Rather Than a Simple Switch
Murphy describes ketamine's effect with an analogy: the drug opens a floodgate, allowing communication to flow more freely through the brain and increasing its flexibility. In that view, the important question is not only how strong the initial response is, but whether the brain becomes more adaptable afterward.
Why Malleability May Matter More Than the First Surge
Murphy suggests that a patient's clinical response to ketamine is tied more closely to the brain's malleability than to the size of its initial response. He offers an image of rivers in a desert. When a dam is released, water spreads into tributaries and creates connections between places that were previously isolated. Ketamine, he says, helps create a more flexible and densely connected environment in the brain.
But that is not the end of the story. For the effect to be useful, researchers need to understand how the water is flowing. The current analysis, Murphy explains, examines how the surge of glutamate released by ketamine needs to move through brain networks to produce a clinical response.
Mapping Time-Dependent Brain Changes
The study examined time-dependent changes in resting-state O-information following ketamine infusion, according to a figure published with the paper. O-information is a measure used to capture higher-order interactions among brain regions, going beyond simple pairwise connections. In practical terms, it helps researchers see how coordinated activity across networks reorganizes after treatment.
By tracking these patterns over time, the team identified shifts that were linked to depression improvement. That temporal detail is important. If ketamine's benefits depend on a sequence of network changes, then measuring the brain only before and immediately after treatment could miss the window in which the most meaningful reorganization occurs.
What This Means for Treatment-Resistant Depression
Treatment-resistant depression is a heavy burden for patients and families. Standard antidepressants can take weeks to work, and many people try multiple medications without relief. Ketamine's appeal lies in its speed, but speed alone does not guarantee lasting improvement. Understanding the brain changes that accompany response could help clinicians predict who is most likely to benefit and how to sustain the effect.
The Texas A&M findings point toward potential biological markers. If specific patterns of brain activity after ketamine are associated with improvement, those patterns could eventually help guide treatment selection, dosing, or timing. They could also inform strategies that combine ketamine with psychotherapy or other interventions while the brain is in a more flexible state.
At the same time, the study is not a finished roadmap. It identifies associations between brain activity and clinical improvement, not a simple cause-and-effect chain. The researchers emphasize the need to understand how glutamate-driven communication flows after treatment, which suggests that future work will need to test whether modifying those flows changes outcomes.
Open Questions and Next Steps
- How do the time-specific brain patterns differ between older adults who respond to ketamine and those who do not?
- Can resting-state O-information or related measures serve as practical biomarkers in clinical settings?
- What role do age-related changes in brain structure and function play in shaping ketamine's effects?
- How can clinicians balance ketamine's rapid antidepressant potential against safety concerns in older patients with other health conditions?
- Do the findings in older U.S. veterans generalize to broader older adult populations, including those with different health profiles and medication histories?
The Bottom Line
For older adults with treatment-resistant depression, ketamine may do more than provide a brief lift in mood. It may open a window of heightened brain flexibility, and the way that flexibility unfolds over time appears to matter for clinical improvement. The Texas A&M team's analysis adds a crucial piece to the puzzle by focusing on an age group that has often been excluded from ketamine research. More work is needed, but the results suggest that the future of ketamine treatment may depend less on the drug alone and more on understanding the brain's shifting patterns after the infusion.
This article is based on reporting by Medical Xpress. Read the original article.
Originally published on medicalxpress.com
